Abstract

Protein Tyrosine Phosphatase 1B (PTP1B) is the prototypical protein tyrosine phosphatase and plays an essential role in the regulation of several kinase-driven signalling pathways. PTP1B displays a preference for bisphosphorylated substrates. Here we identify PTP1B as an inhibitor of IL-6 and show that, in vitro, it can dephosphorylate all four members of the JAK family. In order to gain a detailed understanding of the molecular mechanism of JAK dephosphorylation, we undertook a structural and biochemical analysis of the dephosphorylation reaction. We identified a product-trapping PTP1B mutant that allowed visualisation of the tyrosine and phosphate products of the reaction and a substrate-trapping mutant with a vastly decreased off-rate compared to those previously described. The latter mutant was used to determine the structure of bisphosphorylated JAK peptides bound to the enzyme active site. These structures revealed that the downstream phosphotyrosine preferentially engaged the active site, in contrast to the analogous region of IRK. Biochemical analysis confirmed this preference. In this binding mode, the previously identified second aryl binding site remains unoccupied and the non-substrate phosphotyrosine engages Arg47. Mutation of this arginine disrupts the preference for the downstream phosphotyrosine. This study reveals a previously unappreciated plasticity in how PTP1B interacts with different substrates.

Structural and biochemical characterization of the phosphastase and immune checkpoint PTP1B reveals the molecular basis of PTBP1B/JAK interaction and plasticity of substrate recognition by PTP1B.

Details

Title
Structure guided studies of the interaction between PTP1B and JAK
Author
Morris, Rhiannon 1   VIAFID ORCID Logo  ; Keating, Narelle 1 ; Tan, Cyrus 1 ; Chen, Hao 1 ; Laktyushin, Artem 2 ; Saiyed, Tamanna 2 ; Liau, Nicholas P. D. 1 ; Nicola, Nicos A. 1 ; Tiganis, Tony 3   VIAFID ORCID Logo  ; Kershaw, Nadia J. 1   VIAFID ORCID Logo  ; Babon, Jeffrey J. 1   VIAFID ORCID Logo 

 Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889); The University of Melbourne, Royal Parade, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
 Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) (ISNI:0000 0004 0432 4889) 
 Monash University, Monash Biomedicine Discovery Institute, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Department of Biochemistry and Molecular Biology, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Peter MacCallum Cancer Centre, Cancer Immunology Program, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434) 
Pages
641
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
23993642
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2825652309
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.